

Annexe 1 de la loi-programme

La liste des spécialités qui sont exclues du chiffre d'affaires sur base duquel la contribution, visée à l'article 191, alinéa 1^{er}, 35°, de la loi relative à l'assurance obligatoire soins de santé et indemnités coordonnée le 14 juillet 1994, est calculée, comprend :

ATC level 5	ATC description The Anatomical Therapeutic Chemical code: a unique code assigned to a medicine according to the organ or system it works on and how it works. The classification system is maintained by the World Health Organization (WHO).	Route of administration	Date of inclusion
A - Alimentary tract and metabolism			
	A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)		
A02BC05	ESOMEPRAZOLE	intravenous use	1 December 2023
	A03B - Belladonna and derivatives, plain		
A03BA01	ATROPINE	intramuscular, intravenous, subcutaneous use	1 December 2023
	A03F - Propulsives		
A03FA01	METOCLOPRAMIDE	intramuscular, intravenous, subcutaneous use	1 December 2023
	A07A - Intestinal antiinfectives		
A07AA12	FIDAXOMICIN	oral use	1 December 2023
	A07B - Intestinal adsorbents		
A07BA01	MEDICINAL CHARCOAL	oral use	1 December 2023
	A10A - Insulins and analogues		
A10AB01	INSULIN HUMAN (fast-acting)	intramuscular, intravenous, subcutaneous use	1 December

			ber 2023
A10AC 01	INSULIN HUMAN (intermediate-acting)	intramuscular, intravenous, subcutaneous use	1 Decem ber 2023
A10AD 01	INSULIN HUMAN (intermediate - or long-acting combined with fast-acting)	intramuscular, intravenous, subcutaneous use	1 Decem ber 2023
	A12C - Other mineral supplements		
A12CC 02	MAGNESIUM SULFATE	intravenous, intramuscular use	1 Decem ber 2023
	A16A - Other alimentary tract and metabolism products		
A16AB 02	IMIGLUCERASE	intravenous use	1 Decem ber 2023
B - Blood and blood forming organs			
	B01A - Antithrombotic agents		
B01AA 03	WARFARIN	oral use	1 Decem ber 2023
B01AB 01	HEPARIN	haemodialysis, intraarterial, intravenous, subcutaneous use	1 Decem ber 2023
B01AB 02	ANTITHROMBIN III	intravenous use	1 Decem ber 2023
B01AC 04	CLOPIDOGREL	oral use	1 Decem ber 2023
B01AC 16	EPTIFIBATIDE	intravenous use	1 Decem ber 2023
B01AD 02	ALTEPLASE	intravenous use	1 Decem ber 2023

B01AD 11	TENECTEPLASE	intravenous use	1 Decem ber 2023
B01AE 07	DABIGATRAN	oral use	1 Decem ber 2023
	B02A - Antifibrinolytics		
B02AA 02	TRANEXAMIC ACID	oral, intravenous use	1 Decem ber 2023
	B02B - Vitamin K and other hemostatics		
B02BA 01	PHYTOMENADIONE	intramuscular, intravenous, oral use	1 Decem ber 2023
B02BB 01	HUMAN FIBRINOGEN	intravenous use	1 Decem ber 2023
B02BD 01	HUMAN PROTHROMBIN COMPLEX	intravenous use	16 Decem ber 2024
B02BD 02	HUMAN COAGULATION FACTOR VIII	intravenous use	1 Decem ber 2023
B02BD 04	HUMAN COAGULATION FACTOR IX	intravenous use	1 Decem ber 2023
B02BD 05	HUMAN COAGULATION FACTOR VII	intravenous use	16 Decem ber 2024
B02BD 07	HUMAN COAGULATION FACTOR XIII	intravenous use	16 Decem ber 2024
B02BD 08	EPTACOG ALFA	intravenous use	16 Decem ber 2024
	B03B - Vitamin B12 and folic acid		
B03BA 03	HYDROXOCOBALAMIN	intravenous, intramuscular, subcutaneous, oral use	1 Decem

			ber 2023
	B05A - Blood and related products		
B05AA 01	ALBUMIN	intravenous use	1 Decem ber 2023
B05AA 02	PLASMA PROTEIN FRACTION	intravenous use	1 Decem ber 2023
	B05B - IV solutions		
B05BB 01	POTASSIUM CHLORIDE	intravenous use	1 Decem ber 2023
B05BC 01	MANNITOL	intravenous use	1 Decem ber 2023
	B05X - IV solution additives		
B05XA 01	POTASSIUM CHLORIDE	intravenous use	1 Decem ber 2023
B05XA 05	MAGNESIUM SULFATE	intravenous use	1 Decem ber 2023
	B06A - Other hematological agents		
B06AB 01	HUMAN HEMIN	intravenous use	1 Decem ber 2023
B06AC 01	COMPLEMENT C1 ESTERASE INHIBITOR	intravenous, subcutaneous use	1 Decem ber 2023
C - Cardiovascular system			
	C01A - Cardiac glycosides		
C01AA 05	DIGOXIN	oral, intravenous use	1 Decem ber 2023
	C01B - Antiarrhythmics, class I and III		

C01BB 01	LIDOCAINE	parenteral use	1 Decem ber 2023
C01BB 02	MEXILETINE	oral use	1 Decem ber 2023
C01BC 04	FLECAINIDE	oral use	1 Decem ber 2023
C01BD 01	AMIODARONE	intravenous use	1 Decem ber 2023
	C01C - Cardiac stimulants excl cardiac glycosides		
C01CA 02	ISOPRENALINE	intravenous use	1 Decem ber 2023
C01CA 03	NOREPINEPHRINE	intravenous use	1 Decem ber 2023
C01CA 04	DOPAMINE	intravenous use	1 Decem ber 2023
C01CA 07	DOBUTAMINE	intravenous use	1 Decem ber 2023
C01CA 24	EPINEPHRINE	endotracheopulmonary, intracardiac, intraosseous, intramuscular, intravenous, subcutaneous use	1 Decem ber 2023
C01CA 26	EPHEDRINE	intravenous, intramuscular, subcutaneous use	1 Decem ber 2023
C01CE 02	MILRINONE	intravenous use	1 Decem ber 2023
	C01D - Vasodilators used in cardiac diseases		
C01DA 02	GLYCERYL TRINITRATE	intravenous, sublingual use	1 Decem

			ber 2023
	C01E - Other cardiac preparations		
C01EB 10	ADENOSINE	intravenous use	1 Decem ber 2023
	C02A - Antiadrenergic agents, centrally acting		
C02AB 01	METHYLDOPA (levorotatory)	oral use	1 Decem ber 2023
C02AB 02	METHYLDOPA (racemic)	oral use	1 Decem ber 2023
C02AC 01	CLONIDINE	intramuscular, intravenous, subcutaneous, oral use	1 Decem ber 2023
	C02D - Arteriolar smooth muscle, agents acting on		
C02DD 01	SODIUM NITROPRUSSIDE	intravenous use	1 Decem ber 2023
	C03C - High-ceiling diuretics		
C03CA 01	FUROSEMIDE	intravenous, intramuscular use	1 Decem ber 2023
	C07A - Beta blocking agents		
C07AA 05	PROPRANOLOL	oral use	1 Decem ber 2023
C07AG 01	LABETALOL	intravenous use	1 Decem ber 2023
	C08C - Selective calcium channel blockers with mainly vascular effects		
C08CA 06	NIMODIPINE	intravenous, intracisternal use	1 Decem

			ber 2023
	C08D - Selective calcium channel blockers with direct cardiac effects		
C08DA 01	VERAPAMIL	intravenous use	1 Decem ber 2023
G - Genito urinary system and sex hormones			
	G02A - Uterotonics		
G02AB 01	METHYLERGOMETRINE	intramuscular,intrauterine, intravenous, subcutaneous use	1 Decem ber 2023
	G03X - Other sex hormones and modulators of the genital system		
G03XB 01	MIFEPRISTONE	oral use	1 Decem ber 2023
H - Systemic hormonal preparations, excl sex hormones and insulins			
	H01B - Posterior pituitary lobe hormones		
H01BA 02	DESMOPRESSIN	intramuscular, intravenous, subcutaneous use	1 Decem ber 2023
H01BB 02	OXYTOCIN	intramuscular, intravenous use	1 Decem ber 2023
H01BB 03	CARBETOCIN	intramuscular, intravenous use	1 Decem ber 2023
	H02A - Corticosteroids for systemic use, plain		
H02AA 02	FLUDROCORTISONE	oral use	1 Decem ber 2023

H02AB04	METHYLPREDNISOLONE	intraarticular, intrabursal, intradermal, intralesional, intramuscular, intravenous, periarticular, rectal use	1 December 2023
H02AB06	PREDNISOLONE	oral use	1 December 2023
H02AB09	HYDROCORTISONE	intraarticular, intramuscular, intravenous, oral use	1 December 2023
	H03B - Antithyroid preparations		
H03BA02	PROPYLTHIOURACIL	oral use	1 December 2023
H03BB01	CARBIMAZOLE	oral use	1 December 2023
H03BB02	THIAMAZOLE	oral use	1 December 2023
	H04A - Glycogenolytic hormones		
H04AA01	GLUCAGON	intramuscular, intravenous, nasal, subcutaneous use	1 December 2023
J - Antiinfectives for systemic use			
	J01A - Tetracyclines		
J01AA02	DOXYCYCLINE	oral use	1 December 2023
	J01C - Beta-lactam antibacterials, penicillins		
J01CA01	AMPICILLIN	intramuscular, intravenous use	1 December 2023
J01CA04	AMOXICILLIN	oral, intravenous, intramuscular use	1 December 2023
J01CE01	BENZYLPENICILLIN	intraarticular, intramuscular, intrapleural, intrathecal, intravenous use	1 December

			ber 2023
J01CE02	PHENOXYMETHYLPENICILLIN	oral use	1 Decem ber 2023
J01CE08	BENZATHINE BENZYL PENICILLIN	intramuscular use	1 Decem ber 2023
J01CF02	CLOXACILLIN	intravenous, intramuscular use	1 Decem ber 2023
J01CF05	FLUCLOXACILLIN	inhalation, intraarticular, intramuscular, intrapleural, intravenous, oral use	1 Decem ber 2023
J01CR02	AMOXICILLIN, CLAVULANIC ACID	oral, intravenous use	1 Decem ber 2023
J01CR05	PIPERACILLIN, TAZOBACTAM	intravenous use	1 Decem ber 2023
	J01D - Other beta-lactam antibacterials		
J01DC02	CEFUROXIME	oral use	1 Decem ber 2023
J01DD01	CEFOTAXIME	intramuscular, intravenous use	1 Decem ber 2023
J01DD02	CEFTAZIDIME	intramuscular, intravenous use	1 Decem ber 2023
J01DD04	CEFTRIAZONE	intramuscular, intravenous, subcutaneous use	1 Decem ber 2023
J01DD08	CEFIXIME	oral use	1 Decem ber 2023
J01DD52	CEFTAZIDIME, AVIBACTAM	intravenous use	1 Decem ber 2023

J01DF01	AZTREONAM	intramuscular, intravenous use	1 December 2023
J01DH56	CILASTATIN SODIUM, IMIPENEM, RELEBACTAM	intravenous use	1 December 2023
J01DI54	TAZOBACTAM, CEFTOLOZANE	intravenous use	1 December 2023
	J01E - Sulfonamides and trimethoprim		
J01EA01	TRIMETHOPRIM	oral use	1 December 2023
J01EE01	CO-TRIMOXAZOLE	oral, intravenous use	1 December 2023
	J01F - Macrolides, lincosamides and streptogramins		
J01FA01	ERYTHROMYCIN	intravenous use	1 December 2023
J01FA09	CLARITHROMYCIN	intravenous use	1 December 2023
J01FA10	AZITHROMYCIN	intravenous, oral use	1 December 2023
J01FF01	CLINDAMYCIN	intramuscular, intravenous use	1 December 2023
	J01G - Aminoglycoside antibacterials		
J01GB01	TOBRAMYCIN	inhalation, intramuscular, intravenous use	1 December 2023
J01GB03	GENTAMICIN	intramuscular, intravenous, subconjunctival use	1 December 2023

J01GB06	AMIKACIN	intramuscular, intravenous use	1 December 2023
	J01M - Quinolone antibacterials		
J01MA02	CIPROFLOXACIN	intravenous, oral use	1 December 2023
J01MA12	LEVOFLOXACIN	intravenous use	1 December 2023
	J01X - Other antibacterials		
J01XA01	VANCOMYCIN	intraperitoneal, intravenous, oral use	1 December 2023
J01XA02	TEICoplanin	intramuscular, intravenous use	1 December 2023
J01XB01	COLISTIN	inhalation, intrathecal, intravenous use	1 December 2023
J01XD01	METRONIDAZOLE	intravenous use	1 December 2023
J01XX01	FOSFOMYCIN	intravenous use	1 December 2023
	J02A - Antimycotics for systemic use		
J02AA01	AMPHOTERICIN B	intravenous use	1 December 2023
J02AC04	POSACONAZOLE	intravenous use	1 December 2023
J02AC05	ISAVUCONAZOLE	intravenous, oral use	16 December 2024

	J04A - Drugs for treatment of tuberculosis		
J04AB02	RIFAMPICIN	oral use	1 December 2023
J04AB04	RIFABUTIN	oral use	1 December 2023
J04AC01	ISONIAZID	oral use	1 December 2023
J04AK02	ETHAMBUTOL	oral use	1 December 2023
J04AK05	BEDAQUILINE	oral use	1 December 2023
J04AM02	ISONIAZID, RIFAMPICIN	oral use	1 December 2023
	J04B - Drugs for treatment of lepra		
J04BA02	DAPSONE	oral use	1 December 2023
	J05A - Direct acting antivirals		
J05AB01	ACICLOVIR	intravenous use	1 December 2023
J05AB06	GANCICLOVIR	intravenous use	1 December 2023
J05AB14	VALGANCICLOVIR	oral use	1 December 2023
J05AD01	FOSCARNET	intravenous use	1 December 2023

J05AF01	ZIDOVUDINE	intravenous, oral use	1 December 2023
J05AF05	LAMIVUDINE	oral use	1 December 2023
J05AF06	ABACAVIR	oral use	1 December 2023
J05AF09	EMTRICITABINE	oral use	1 December 2023
J05AG01	NEVIRAPINE	oral use	1 December 2023
J05AR02	ABACAVIR, LAMIVUDINE	oral use	1 December 2023
	J06B - Immunoglobulins		
J06BA01	HUMAN NORMAL IMMUNOGLOBULIN	subcutaneous use	1 December 2023
J06BA02	HUMAN NORMAL IMMUNOGLOBULIN	intravenous use	1 December 2023
J06BB01	HUMAN ANTI-D IMMUNOGLOBULIN	intramuscular, intravenous use	1 December 2023
J06BB02	HUMAN TETANUS IMMUNOGLOBULIN	intramuscular, subcutaneous use	1 December 2023
J06BB04	HUMAN HEPATITIS B IMMUNOGLOBULIN	intramuscular, intravenous, subcutaneous use	16 December 2024
J06BB05	HUMAN RABIES IMMUNOGLOBULIN	intramuscular use	1 December 2023
	J07A - Bacterial vaccines		

J07AE01	CHOLERA VACCINE (inactivated)	oral use	1 December 2023
J07AH07	MENINGOCOCCAL GROUP C VACCINE	intramuscular use	1 December 2023
J07AH09	MENINGOCOCCAL GROUP B VACCINE	intramuscular use	1 December 2023
J07AJ51	DIPHTHERIA, TETANUS, PERTUSSIS VACCINE (inactivated, whole cell)	intramuscular, subcutaneous use	1 December 2023
J07AJ52	DIPHTHERIA, TETANUS, PERTUSSIS VACCINE (purified antigen)	intramuscular, subcutaneous use	1 December 2023
J07AM51	DIPHTHERIA, TETANUS VACCINE	intramuscular, subcutaneous use	1 December 2023
J07AP03	TYPHOID VACCINE (polysaccharide)	intramuscular, subcutaneous use	1 December 2023
	J07B - Viral vaccines		
J07BA02	ENCEPHALITIS (Japanese, whole virus, inactivated)	intramuscular use	1 December 2023
J07BB01	INFLUENZA VACCINE (various forms, strains)	intramuscular use	1 December 2023
J07BB02	INFLUENZA VACCINE (various forms, strains)	intramuscular, subcutaneous use	1 December 2023
J07BC01	HEPATITIS B VACCINE	intramuscular, subcutaneous use	1 December 2023
J07BC02	HEPATITIS A VACCINE	intramuscular, subcutaneous use	1 December 2023
J07BC20	HEPATITIS A AND B VACCINE	intramuscular, subcutaneous use	16 December

			ber 2024
J07BD5 2	MEASLES, MUMPS, RUBELLA VACCINE	intramuscular, subcutaneous use	1 Decem ber 2023
J07BD5 4	MEASLES, MUMPS, RUBELLA, VARICELLA VACCINE	intramuscular, subcutaneous use	1 Decem ber 2023
J07BF0 3	POLIOMYELITIS VACCINE (trivalent)	intramuscular, subcutaneous use	1 Decem ber 2023
J07BG0 1	RABIES VACCINE	intradermal, intramuscular, subcutaneous use	1 Decem ber 2023
J07BH0 2	ROTAVIRUS PENTAVALENT VACCINE	oral use	16 Decem ber 2024
J07BK0 1	VARICELLA VACCINE (live)	intramuscular, subcutaneous use	1 Decem ber 2023
J07BL0 1	YELLOW FEVER VACCINE	intramuscular, subcutaneous use	1 Decem ber 2023
J07BM 01	PAPILLOMAVIRUS VACCINE	intramuscular use	16 Decem ber 2024
J07BM 02	PAPILLOMAVIRUS VACCINE	intramuscular use	16 Decem ber 2024
J07BM 03	HUMAN PAPILLOMAVIRUS VACCINE (9-valent)	intramuscular use	1 Decem ber 2023
	J07C - Bacterial and viral vaccines, combined		
J07CA0 1	DIPHTHERIA, TETANUS, POLIOMYELITIS VACCINE	intramuscular, subcutaneous use	1 Decem ber 2023
J07CA0 2	DIPHTHERIA, TETANUS, PERTUSSIS,	intramuscular, subcutaneous use	1 Decem

	POLIOMYELITIS VACCINE		ber 2023
J07CA06	DIPHTHERIA, TETANUS, PERTUSSIS VACCINE	intramuscular, subcutaneous use	1 December 2023
J07CA12	DIPHTHERIA, TETANUS, PERTUSSIS, POLIOMYELITIS, HEPATITIS B VACCINE	intramuscular use	1 December 2023
L - Antineoplastic and immunomodulating agents			
	L01A - Antineoplastic agents		
L01AA01	CYCLOPHOSPHAMIDE	intramuscular, intravenous, oral use	1 December 2023
L01AA02	CHLORAMBUCIL	oral use	1 December 2023
L01AA03	MELPHALAN	intraarterial, intravenous, oral use	1 December 2023
L01AA06	IFOSFAMIDE	intraarterial, intravenous use	1 December 2023
L01AB01	BUSULFAN	intravenous, oral, subcutaneous use	1 December 2023
L01AB02	TREOSULFAN	intravenous use	1 December 2023
L01AC01	THIOTEPA	intramuscular, intrapericardial, intraperitoneal, intrapleural, intravascular, intravenous use	16 December 2024
L01AX04	DACARBAZINE	intravenous use	1 December 2023
	L01B - Antimetabolites		
L01BA01	METHOTREXATE	epidural, intraarterial, intraarticular, intrabursal, intracoronary, intradiscal, intramuscular, intrathecal, intravenous, oral, periarticular, perineural, rectal,	1 December 2023

		retrobulbar, subconjunctival, subcutaneous, transdermal use	
L01BB02	MERCAPTOPURINE	oral use	1 December 2023
L01BB03	TIOGUANINE	oral use	1 December 2023
L01BB05	FLUDARABINE	epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, oral, perineural, retrobulbar use	1 December 2023
L01BC01	CYTARABINE	intramuscular, intrathecal, intravenous, subcutaneous use	1 December 2023
L01BC02	FLUOROURACIL	intraarterial, intraarticular, intramuscular, intraperitoneal, intrapleural, intravenous use	16 December 2024
L01BC05	GEMCITABINE	intravenous use	1 December 2023
	L01C - Plant alkaloids and other natural products		
L01CA01	VINBLASTINE	epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, perineural, retrobulbar use	1 December 2023
L01CA02	VINCRIStINE	epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, perineural, retrobulbar use	1 December 2023
L01CB01	ETOPOSIDE	epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, oral, perineural, retrobulbar use	1 December 2023
L01CD01	PACLITAXEL	intravenous use	1 December 2023
L01CE01	TOPOTECAN	intravenous, oral use	1 December 2023
	L01D - Cytotoxic antibiotics and related substances		

L01DB01	DOXORUBICIN	intravenous, intravesical use	1 December 2023
L01DB02	DAUNORUBICIN	intravenous use	1 December 2023
L01DB03	EPIRUBICIN	epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, intravesical, perineural, retrobulbar use	1 December 2023
L01DB06	IDARUBICIN	intravenous use	1 December 2023
L01DB07	MITOXANTRONE	intrapleural, intravenous use	16 December 2024
L01DC01	BLEOMYCIN	intraarterial, intramuscular, intraperitoneal, intrapleural, intratumoral, intravenous, subcutaneous use	1 December 2023
L01DC03	MITOMYCIN	intravenous, intravesical use	1 December 2023
	L01E - Protein kinase inhibitors		
L01EA03	NILOTINIB	oral use	1 December 2023
L01EC02	DABRAFENIB	oral use	16 December 2024
L01EC03	ENCORAFENIB	oral use	16 December 2024
L01EE01	TRAMETINIB	oral use	16 December 2024
L01EL01	IBRUTINIB	oral use	16 December 2024
	L01F - Monoclonal antibodies and		

	antibody drug conjugates		
L01FA03	OBINUTUZUMAB	intravenous use	16 December 2024
L01FB01	INOTUZUMAB OZOGAMICIN	intravenous use	16 December 2024
L01FC01	DARATUMUMAB	intravenous, subcutaneous use	16 December 2024
L01FF03	DURVALUMAB	intravenous use	16 December 2024
L01FX02	GEMTUZUMAB OZOGAMICIN	intravenous use	16 December 2024
L01FX05	BRENTUXIMAB VEDOTIN	intravenous use	16 December 2024
L01FX17	SACITUZUMAB GOVITECAN	intravenous use	16 December 2024
	L01X - Other neoplastic agents		
L01XA01	CISPLATIN	epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, perineural, retrobulbar use	1 December 2023
L01XA02	CARBOPLATIN	epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, perineural, retrobulbar use	1 December 2023
L01XA03	OXALIPLATIN	epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, perineural, retrobulbar use	1 December 2023
L01XB01	PROCARBAZINE	oral use	1 December 2023
L01XF01	TRETINOIN	oral use	1 December 2023

L01XJ01	VISMODEGIB	oral use	16 December 2024
L01XX05	HYDROXYCARBAMIDE	oral use	1 December 2023
L01XX23	MITOTANE	oral use	16 December 2024
L01XX24	PEGASPARGASE	intramuscular, intravenous use	1 December 2023
	L02B - Hormone antagonists and related agents		
L02BA01	TAMOXIFEN	oral use	1 December 2023
	L03A - Immunostimulants		
L03AB11	PEGINTERFERON ALFA-2A	subcutaneous use	1 December 2023
L03AX03	BCG VACCINE (various forms)	intravesical use	1 December 2023
L03AX13	GLATIRAMER	intraarticular, intravenous, periarticular, subcutaneous, transdermal use	1 December 2023
L03AX16	PLERIXAFOR	subcutaneous use	1 December 2023
	L04A - Immunosuppressants		
L04AA03	ANTILYMPHOCYTE IMMUNOGLOBULIN (horse)	intravenous use	1 December 2023
L04AA04	ANTITHYMOCYTE IMMUNOGLOBULIN (rabbit)	intravenous use	16 December 2024

L04AC02	BASILIXIMAB	intravenous use	1 December 2023
L04AC03	ANAKINRA	subcutaneous use	1 December 2023
L04AD01	CICLOSPORIN	intravenous, oral use	1 December 2023
L04AD02	TACROLIMUS	intravenous, oral use	1 December 2023
L04AH01	SIROLIMUS	oral use	1 December 2023
L04AX02	THALIDOMIDE	oral use	1 December 2023
L04AX03	METHOTREXATE	oral use	1 December 2023
M - Musculo-skeletal system			
	M01C - Specific antirheumatic agents		
M01CC01	PENICILLAMINE	oral use	1 December 2023
	M03A - Muscle relaxants, peripherally acting agents		
M03AB01	SUXAMETHONIUM	intramuscular, intraosseous, intravenous use	1 December 2023
M03AC04	ATRACURIUM	intravenous use	1 December 2023
M03AC09	ROCURONIUM	intravenous use	1 December 2023

M03AC11	CISATRACURIUM	intravenous use	1 December 2023
	M03C - Muscle relaxants, directly acting agents		
M03CA01	DANTROLENE	intravenous use	1 December 2023
N - Nervous system			
	N01A - Anesthetics, general		
N01AH01	FENTANYL	epidural, intramuscular, intravenous use	1 December 2023
N01AH03	SUFENTANIL	epidural, intravenous use	1 December 2023
N01AH06	REMIFENTANIL	intramuscular, intravenous use	1 December 2023
N01AX03	KETAMINE	intramuscular, intravenous use	1 December 2023
N01AX10	PROPOFOL	intravenous use	1 December 2023
N01AX14	ESKETAMINE	intramuscular, intravenous use	1 December 2023
	N02A - Opioids		
N02AA01	MORPHINE	epidural, intramuscular, intravenous, subcutaneous use	1 December 2023
	N02B - Other analgesics and antipyretics		
N02BE01	PARACETAMOL	intravenous use	1 December 2023
	N03A - Antiepileptics		

N03AA 02	PHENOBARBITAL	intramuscular, intravenous, oral use	1 Decem ber 2023
N03AB 02	PHENYTOIN	intramuscular, intravenous, oral use	1 Decem ber 2023
N03AD 01	ETHOSUXIMIDE	oral use	1 Decem ber 2023
N03AE 01	CLONAZEPAM	oral use	1 Decem ber 2023
N03AF 01	CARBAMAZEPINE	oral use	1 Decem ber 2023
N03AG 01	VALPROIC ACID	intravenous, oral use	1 Decem ber 2023
N03AG 04	VIGABATRIN	oral use	1 Decem ber 2023
	N04A - Anticholinergic agents		
N04AA 02	BIPERIDEN	intramuscular, intravenous use	1 Decem ber 2023
	N05A - Antipsychotics		
N05AD 01	HALOPERIDOL	intraarticular, intramuscular, intravascular, intravenous, oral use	1 Decem ber 2023
N05AH 03	OLANZAPINE	intramuscular use	1 Decem ber 2023
N05AN 01	LITHIUM	oral use	1 Decem ber 2023
	N05B - Anxiolytics		
N05BA 01	DIAZEPAM	intramuscular, intravenous, rectal use	1 Decem ber 2023

N05BA 06	LORAZEPAM	intramuscular, intravenous use	1 Decem ber 2023
	N05C - Hypnotics and sedatives		
N05CD 08	MIDAZOLAM	intramuscular, intravenous, subcutaneous, rectal use	1 Decem ber 2023
N05CM 18	DEXMEDETOMIDINE	intravenous, subcutaneous use	1 Decem ber 2023
	N06A - Antidepressants		
N06AX 27	ESKETAMINE	nasal use	1 Decem ber 2023
	N06B - Psychostimulants, agents used for ADHD and nootropics		
N06BC 01	CAFFEINE	intravenous, oral use	1 Decem ber 2023
	N07A - Parasympathomimetic s		
N07AA 01	NEOSTIGMINE	intramuscular, intravenous, subcutaneous use	1 Decem ber 2023
	N07X - Other nervous system drugs		
N07XX 02	RILUZOLE	oral use	1 Decem ber 2023
P - Antiparasitic products, insecticides and repellents			
	P01A - Agents against amoebiasis and other protozoal diseases		
P01AB 01	METRONIDAZOLE	intravenous use	1 Decem ber 2023

	P01C - Agents against leishmaniasis and trypanosomiasis		
P01CX01	PENTAMIDINE	inhalation, intramuscular, intravenous use	1 December 2023
	P02C - Antinematodal agents		
P02CA03	ALBENDAZOLE	oral use	1 December 2023
R - Respiratory system			
	R03A - Adrenergics, inhalants		
R03AC02	SALBUTAMOL	inhalation, nasal, oral use	1 December 2023
	R03B - Other drugs for obstructive airway diseases, inhalants		
R03BB01	IPRATROPIUM	inhalation, oral use	1 December 2023
	R03C - Adrenergics for systemic use		
R03CA02	EPHEDRINE	intramuscular, intravenous, subcutaneous use	1 December 2023
R03CC02	SALBUTAMOL	intramuscular, intravenous, subcutaneous use	1 December 2023
	R05C - Expectorants, excl combinations with cough suppressants		
R05CB01	ACETYLCYSTEINE	intravenous use	1 December 2023
S - Sensory organs			
	S01E - Antiglaucoma preparations and miotics		
S01EB01	PILOCARPINE	ocular use	1 December 2023

S01EB09	ACETYLCHOLINE	intraocular use	1 December 2023
S01EC01	ACETAZOLAMIDE	oral use	1 December 2023
	S01F - Mydriatics and cycloplegics		
S01FA04	CYCLOPENTOLATE	ocular use	1 December 2023
	S01L - Ocular vascular disorder agents		
S01LA01	VERTEPORFIN	intravenous use	1 December 2023
	S02A - Antiinfectives		
	S03A - Antiinfectives		
V - Various			
	V03A - All other therapeutic products		
V03AB06	SODIUM THIOSULFATE	intravenous use	1 December 2023
V03AB14	PROTAMINE	intravenous use	1 December 2023
V03AB15	NALOXONE	intramuscular, intravenous, subcutaneous use	1 December 2023
V03AB17	METHYLTHIONINIUM	intravenous use	1 December 2023
V03AB23	ACETYLCYSTEINE	intravenous use	1 December 2023
V03AB25	FLUMAZENIL	intravenous use	1 December 2023
V03AB33	HYDROXOCOBALAMIN	intramuscular, intravenous, oral, subcutaneous use	1 December

			ber 2023
V03AB 34	FOMEPIZOLE	intravenous use	1 Decem ber 2023
V03AB 35	SUGAMMADEX	intravenous use	1 Decem ber 2023
V03AB 37	IDARUCIZUMAB	intravenous use	1 Decem ber 2023
V03AC 01	DEFEROXAMINE	intramuscular, intraperitoneal, intravenous, subcutaneous use	1 Decem ber 2023
V03AE 01	POLYSTYRENE SULFONIC ACID	oral use	1 Decem ber 2023
V03AF0 1	MESNA	intravenous, oral use	1 Decem ber 2023
V03AF0 2	DEXRAZOXANE	intravenous use	1 Decem ber 2023
V03AF0 3	FOLINIC ACID	intramuscular, intravenous use	1 Decem ber 2023
V03AF0 7	RASBURICASE	intravenous use	1 Decem ber 2023
	V04C - Other diagnostic agents		
V04CF 01	TUBERCULIN	intradermal use	1 Decem ber 2023
	V09G - Cardiovascular system		
V09GA 04	ALBUMIN (Technetium, 99mTc)	intravenous use	1 Decem ber 2023
V09GB 02	ALBUMIN (Iodine, 125I)	intradermal, intratumoral, intravenous, subcutaneous use	1 Decem

			ber 2023
	V10X - Other therapeutic radiopharmaceuticals		
V10XX 03	RADIUM (223RA) DICHLORIDE	intravenous use	16 Decem ber 2024
See websites for contact details			
Heads of Medicines Agencies www.hma.eu European Medicines Agency www.ema.europa.eu European Commission www.commission.europa.eu			

Vu pour être annexé à la loi-programme du **XX.XX.2025.**

Annexe 2 à la loi programme du ...

Chapitre 3. Contributions destinées à rémunérer les activités des comités d'éthique visés à l'article 47/2 de la loi du 7 mai 2017 relative aux essais cliniques de médicaments à usage humain

Pour l'application du présent chapitre, il y a lieu d'entendre par : « loi du 7 mai 2017 » : la loi du 7 mai 2017 relative aux essais cliniques de médicaments à usage humain.

Fait générateur	Redevable	Montant
X.3.1. Une demande d'autorisation d'essai clinique, autre qu'une demande visée au X.3.2., X.3.3., X.3.6., X.3.7. ou X.3.8., où la Belgique agit en tant qu'Etat membre rapporteur	Promoteur d'un essai clinique commercial	7.677,41 euros
X.3.2. Une demande d'autorisation d'essai clinique de phase I où la Belgique agit en tant qu'Etat membre rapporteur	Promoteur d'un essai clinique commercial	7.677,41 euros
X.3.3. Une demande d'autorisation d'essai clinique à faible niveau d'intervention, au sens de l'article 2, paragraphe 2, 3), du règlement (UE) 536/2014, où la Belgique agit en tant qu'Etat membre rapporteur	Promoteur d'un essai clinique commercial	7.677,41 euros
X.3.4. Une demande d'autorisation d'essai clinique, autre qu'une demande visée au X.3.5., où la Belgique agit en tant qu'Etat membre concerné	Promoteur d'un essai clinique commercial	7.677,41 euros
X.3.5. Une demande d'autorisation d'essai clinique à faible niveau d'intervention, au sens de l'article 2, paragraphe 2, 3), du règlement (UE) 536/2014,	Promoteur d'un essai clinique commercial	7.677,41 euros

où la Belgique agit en tant qu'Etat membre concerné		
X.3.6. Une demande d'autorisation d'essai clinique mononational, autre qu'une demande visée au X.3.7. ou au X.3.8.	Promoteur d'un essai clinique commercial	7.677,41 euros
X.3.7. Une demande visée à l'article 22 de la loi du 7 mai 2017	Promoteur d'un essai clinique commercial	7.677,41 euros
X.3.8. Une demande d'autorisation d'essai clinique mononational à faible niveau d'intervention, au sens de l'article 2, paragraphe 2, 3), du règlement (UE) 536/2014	Promoteur d'un essai clinique commercial	7.677,41 euros
X.3.9 Une demande de modification substantielle d'un essai clinique, conformément à l'article 18 du règlement (UE) 536/2014 ou conformément à l'article 22 du règlement (UE) 536/2014, où la Belgique agit en tant qu'Etat membre rapporteur	Promoteur d'un essai clinique commercial	1.605,73 euros
X.3.10. Une demande de modification substantielle d'un essai clinique, conformément à l'article 18 du règlement (UE) 536/2014 ou conformément à l'article 22 du règlement (UE) 536/2014, où la Belgique agit en tant qu'Etat membre concerné	Promoteur d'un essai clinique commercial	1.605,73 euros
X.3.11. Une demande de modification substantielle d'un essai clinique, conformément à l'article 20 du règlement (UE) 536/2014	Promoteur d'un essai clinique commercial	518,73 euros

X.3.12. Une demande en recours gracieux, conformément à l'article 48 de la loi du 7 mai 2017	Promoteur d'un essai clinique commercial	7.677,41 euros
X.3.13. Une demande où uniquement les aspects relevant de la partie I ou de la partie II du rapport d'évaluation relatif à une demande d'autorisation d'essai clinique visée au X.3.1., X.3.2., X.3.3., X.3.4. ou X.3.5. sont évalués, conformément à l'article 11 du règlement (UE) 536/2014	Promoteur d'un essai clinique commercial	3.838,71 euros
X.3.14. Une demande où uniquement les aspects relevant de la partie I ou de la partie II du rapport d'évaluation relatif à une demande d'autorisation d'essai clinique visée au X.3.6., X.3.7. ou X.3.8. sont évalués, conformément à l'article 11 du règlement (UE) 536/2014	Promoteur d'un essai clinique commercial	3.838,71 euros
X.3.15. Contribution supplémentaire : la demande d'autorisation d'essai clinique ou la demande de modification substantielle via une procédure accélérée à la demande du Collège.	Promoteur d'un essai clinique commercial	5.122,82 euros, en complément des montants visés aux X.3.1., X.3.2., X.3.3., X.3.4., X.3.5., X.3.9, X.3.10., X.3.11. ou X.3.13.

Annexe 3 à la loi programme du ...

Annexe – Montant de la subvention pour l'application de l'article 47/2, et modalités de paiement

Chapitre 1er. Montant de la subvention

I.1. La subvention est déterminée en fonction du nombre de demandes et de notifications.

I.2. Les montants par demande et par notification sont forfaitaires et sont fixés conformément à l'article 47/2, alinéa 1^{er} et 3.

Chapitre II – Modalités de paiement

II.1.1. Le Service public fédéral Santé publique, Sécurité de la Chaîne alimentaire et Environnement envoie un avis de paiement à l'AFMPS dans un délai de 15 jours à partir du premier jour suivant le trimestre auquel la subvention se rapporte. La subvention est fixée tous les trois mois.

II.1.2. En vue de l'application de ce chapitre, le Service public fédéral Santé publique, Sécurité de la Chaîne alimentaire et Environnement désigne un représentant permanent, ainsi qu'un ou plusieurs suppléants.

II.3. L'avis de paiement est signé par une personne mentionnée au point II.1.2 et contient les informations suivantes sous peine de nullité:

II.3.1

le nombre de demandes et de notifications pour le mois concerné selon la répartition fixée conformément à l'article 47/2, alinéa 1^{er} et 3;

II.3.2

le montant de la subvention due;

II.3.3

le numéro de compte sur lequel le paiement doit être effectué;

II.3.4

la notification unique à ajouter au paiement.

II.4.1. L'AFMPS effectue le paiement dans un délai de 30 jours à partir du premier jour suivant la réception de l'avis de paiement.